Tech Company Financing Transactions

Poseida Therapeutics Funding Round

Poseida Therapeutics, based in San Diego, raised $30.5 million in investment from Longitude Capital Management, Malin and Tavistock Life Sciences.

Transaction Overview

Announced On
4/4/2018
Transaction Type
Venture Equity
Amount
$30,500,000
Round
Series B
Proceeds Purpose
Proceeds from this financing will be used to further advance a pipeline of autologous and allogeneic CAR-T immunotherapies, as well as gene therapies, using Poseida's suite of gene engineering technologies.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
9390 Towne Centre Dr. 200
San Diego, CA 92121
USA
Email Address
Overview
Poseida Therapeutics (Nasdaq: PSTX) utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need.
Profile
Poseida Therapeutics LinkedIn Company Profile
Social Media
Poseida Therapeutics Company Twitter Account
Company News
Poseida Therapeutics News
Facebook
Poseida Therapeutics on Facebook
YouTube
Poseida Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Eric Ostertag
  Eric Ostertag LinkedIn Profile  Eric Ostertag Twitter Account  Eric Ostertag News  Eric Ostertag on Facebook
Chief Medical Officer
Matthew Spear
  Matthew Spear LinkedIn Profile  Matthew Spear Twitter Account  Matthew Spear News  Matthew Spear on Facebook
Vice President
Devon Shedlock
  Devon Shedlock LinkedIn Profile  Devon Shedlock Twitter Account  Devon Shedlock News  Devon Shedlock on Facebook
VP - Bus. Development
Mark Gergen
  Mark Gergen LinkedIn Profile  Mark Gergen Twitter Account  Mark Gergen News  Mark Gergen on Facebook
VP - Engineering
Martin Giedlin
  Martin Giedlin LinkedIn Profile  Martin Giedlin Twitter Account  Martin Giedlin News  Martin Giedlin on Facebook
VP - Finance
Johanna Mylet
  Johanna Mylet LinkedIn Profile  Johanna Mylet Twitter Account  Johanna Mylet News  Johanna Mylet on Facebook
VP - Operations
Jennifer Collins
  Jennifer Collins LinkedIn Profile  Jennifer Collins Twitter Account  Jennifer Collins News  Jennifer Collins on Facebook
VP - Regulatory Affairs
Debra Gessner
  Debra Gessner LinkedIn Profile  Debra Gessner Twitter Account  Debra Gessner News  Debra Gessner on Facebook


 

 

Browse more venture capital transactions:

Prev: 4/4/2018: Axonics Modulation Technologies venture capital transaction
Next: 4/4/2018: Chainium venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary